Protalix director awarded 17K options, 8.5K RSUs

PLX disclosed new option and RSU grants to a director, adding to his existing long-dated stock option holdings.

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. (PLX) reported that director Ben Zvi Shmuel received equity-based compensation on September 3, 2026. He was granted 17,000 stock options with an exercise price of $2.59 per share, expiring on September 3, 2036, which vest in 12 equal quarterly installments starting on the grant date.

He was also granted 8,500 restricted stock units, each representing the right to receive one share of common stock after vesting, which likewise vest in 12 equal quarterly installments commencing on the grant date. A footnote states that he also holds prior option grants for additional shares at exercise prices between $1.03 and $1.66 with expirations from June 30, 2032 through September 3, 2035.

Insider Trade Summary

Grant/Award: 25,500 shares

Grant/Award 2 txns

Insider Ben Zvi Shmuel

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F1, F2	17,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F3, F4	8,500	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 17,000 contracts (Direct); Restricted Stock Units — 8,500 contracts (Direct)

Footnotes (4)

1. F1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
2. F2. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
3. F3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
4. F4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Key Figures

New stock options granted: 17,000 options Stock option exercise price: $2.59 per share Option expiration date: September 3, 2036 +5 more

8 metrics

New stock options granted 17,000 options Grant to director on September 3, 2026

Stock option exercise price $2.59 per share Exercise price for 17,000 options granted September 3, 2026

Option expiration date September 3, 2036 Expiration for 17,000 options granted to director

New RSUs granted 8,500 RSUs Grant to director on September 3, 2026

Prior options at $1.09 40,000 options Existing grant expiring June 30, 2032

Prior options at $1.03 10,000 options Existing grant expiring September 7, 2032

Prior options at $1.66 61,676 options Existing grant expiring September 29, 2033

Prior options at $1.64 15,000 options Existing grant expiring September 3, 2035

Key Terms

Stock Options, Restricted Stock Units, exercise price, expiration date, +1 more

5 terms

Stock Options financial

"The shares of common stock underlying the stock options vest in 12 equal"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Restricted Stock Units financial

"Each restricted stock unit (RSU) represents the right to receive"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"options to purchase 40,000 shares of common stock at an exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"underlying the RSUs vest in 12 equal quarterly installments commencing"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What equity awards did PLX grant to director Ben Zvi Shmuel on September 3, 2026?

On September 3, 2026, PLX granted Ben Zvi Shmuel 17,000 stock options at an exercise price of $2.59 per share, expiring on September 3, 2036, and 8,500 restricted stock units tied to PLX common stock.

How do the new PLX stock options granted to the director vest?

The 17,000 stock options granted to the director vest in 12 equal quarterly installments commencing on the date of grant, according to the company’s disclosure.

What are the vesting terms of the new RSUs reported by PLX for its director?

The 8,500 restricted stock units vest in 12 equal quarterly installments commencing on the grant date. Each RSU represents the right to receive, following vesting, one share of PLX common stock.

What options does the PLX director hold in addition to the new 17,000 options?

A footnote states he also has options to purchase 40,000 shares at $1.09 expiring June 30, 2032; 10,000 shares at $1.03 expiring September 7, 2032; 61,676 shares at $1.66 expiring September 29, 2033; and 15,000 shares at $1.64 expiring September 3, 2035.

Were the PLX director’s September 3, 2026 equity grants made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as using a plan, and there is no footnote indicating that these awards were made under a Rule 10b5-1 or similar pre-arranged trading plan.

How many derivative securities does the PLX director hold after the new grants?

The filing shows 17,000 stock options and 8,500 RSUs following these transactions. A footnote also describes four prior option grants for additional shares at exercise prices between $1.03 and $1.66 with expirations from 2032 to 2035.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 06:04 AM Accepted by SEC EDGAR 09/04/2026 - 06:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Zvi Shmuel

(Last) (First) (Middle)

C/O PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET SCIENCE PARK, POB 455

(Street)

CARMIEL 2161401

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.59	09/03/2026		A		17,000		(1)	09/03/2036	Common Stock	17,000	$0	17,000(2)	D
Restricted Stock Units	(3)	09/03/2026		A		8,500		(4)	(4)	Common Stock	8,500	$0	8,500	D

Explanation of Responses:

1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

2. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $1.09 per share that expire on June 30, 2032, (ii) options to purchase 10,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

	/s/ Joseph R. Magnas, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)